Intratect (Human Normal Immunoglobulin)

Human normal immunoglobulin supplies a broad range of IgG antibodies that neutralize pathogens, enhance opsonization, and regulate complement activation. By binding to Fc receptors on immune cells, it also dampens auto‑reactive processes, thereby restoring humoral immunity and reducing inflammation in the targeted conditions.

The dose of Intratect is individualized. The prescribing clinician determines the amount and infusion schedule based on the patient’s weight, IgG level, clinical condition, and response to therapy. Dosing is adjusted as needed during the course of treatment.

Safety data for Intratect in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the Intratect product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Intratect is a pooled human IgG solution comparable to other IVIG brands in terms of composition and therapeutic intent. Differences may exist in manufacturing processes, stabilizers, and approved indications. Clinicians should review product monographs, consider patient tolerance, and evaluate supply chain reliability when selecting an IVIG therapy.

Intratect must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. If the product reaches room temperature during handling, it should be returned to the refrigerator promptly and used within the time frame specified by the manufacturer.

Intratect is given as an intravenous infusion. The solution is diluted according to the product label and administered through a suitable IV line, typically over several hours. Infusion rates are adjusted based on patient tolerance, and vital signs are monitored throughout the procedure.

Serious risks include anaphylaxis, thromboembolic events, acute renal dysfunction, aseptic meningitis, hemolysis, and severe thrombocytopenia. Patients should be observed closely for signs of these reactions, and clinicians must be prepared to intervene promptly if they occur.

Intratect is contraindicated in individuals with a known severe IgA deficiency who have anti‑IgA antibodies, as well as in patients with a history of severe allergic reactions to immunoglobulin products. Caution is also advised for patients with uncontrolled renal disease or active thrombotic disorders.